Pulse Biosciences (NASDAQ:PLSE) Reaches New 1-Year High – Time to Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s stock price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $23.00 and last traded at $22.85, with a volume of 84098 shares changing hands. The stock had previously closed at $20.39.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research note on Thursday, January 2nd.

Pulse Biosciences Price Performance

The business has a 50 day moving average price of $18.68 and a two-hundred day moving average price of $17.79.

Insider Transactions at Pulse Biosciences

In other news, Director Robert W. Duggan purchased 55,256 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average cost of $17.18 per share, with a total value of $949,298.08. Following the completion of the purchase, the director now owns 42,328,717 shares in the company, valued at approximately $727,207,358.06. This represents a 0.13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the sale, the chief executive officer now owns 63,172 shares in the company, valued at approximately $1,100,456.24. This trade represents a 44.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Large investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new stake in Pulse Biosciences during the 4th quarter valued at $193,000. Franklin Resources Inc. bought a new position in shares of Pulse Biosciences in the 3rd quarter worth $378,000. Creative Planning increased its position in Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock valued at $384,000 after buying an additional 11,667 shares in the last quarter. Barclays PLC increased its position in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after buying an additional 23,738 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in Pulse Biosciences during the 3rd quarter valued at about $588,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.